Close Menu

NEW YORK — Immune profiling firm Immunai said on Thursday that it has acquired single-cell genomics software company Dropprint Genomics for an undisclosed amount.

New York City-based Immunai, which has offices in San Francisco and Tel Aviv, said the acquisition is providing it with technologies San Francisco-based Dropprint has developed for handling the computational demands of large-scale single-cell sequencing and for more cost-effectively processing large numbers of patients samples.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.